What is your approach to pediatric or AYA patients with B-cell ALL who relapse after CD-19 CAR-T?  

This is a somewhat nuanced question based on when the patient relapsed after CAR-T, what CAR-T product they received, whether the patient prior received hematopoietic stem cell transplantation (HSCT), other salvage therapies that were prior received as well as number of prior relapses. Multiple str...